Erythropoietic porphyrias: animal models and update in gene-based therapies.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Current Gene Therapy

• Publication date

  2008-05-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/156652308784746477PMID 18537592
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How not to be seen: immune-evasion strategies in gene therapy

  2008cited by this paper
• Development of lentiviral gene therapy for Wiskott Aldrich syndrome

  2008cited by this paper
• Unrelated HSCT in an adolescent affected by congenital erythropoietic porphyria

  2008cited by this paper
• Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells.

  2008cited by this paper
• Murine retroviral but not human cellular promoters induce in vivo erythroid-specific deregulation that can be partially prevented by insulators.

  2007cited by this paper
• The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors.

  2007cited by this paper
• Advances in the treatment of Chronic Granulomatous Disease by gene therapy.

  2007cited by this paper
• Improved human beta-globin expression from self-inactivating lentiviral vectors carrying the chicken hypersensitive site-4 (cHS4) insulator element.

  2007cited by this paper
• Liver transplantation for porphyria: Who, when, and how?

  2007cited by this paper
• In Vivo Selection and Chemoprotection After Drug Resistance Gene Therapy in a Nonmyeloablative Allogeneic Transplantation Setting in Dogs

  2007cited by this paper
• Allogeneic bone marrow transplantation in a 7‐year‐old girl with congenital erythropoietic porphyria: a treatment dilemma

  2007cited by this paper
• Curative bone marrow transplantation in erythropoietic protoporphyria after reversal of severe cholestasis.

  2007cited by this paper
• Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.

  2007cited by this paper
• Gene therapy: X-SCID transgene leukaemogenicity

  2006cited by this paper
• Acquired erythropoietic protoporphyria as a result of myelodysplasia causing loss of chromosome 18

  2006cited by this paper
• Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1

  2006cited by this paper
• Gene transfer in humans using a conditionally replicating lentiviral vector

  2006cited by this paper
• A knock-in mouse model of congenital erythropoietic porphyria.

  2006cited by this paper
• Late‐onset erythropoietic protoporphyria in association with haematological malignancy

  2006cited by this paper
• Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning.

  2006cited by this paper
• Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cells.

  2006cited by this paper
• Ursodesoxycholic acid and heme-arginate are unable to improve hematopoiesis and liver injury in an erythropoietic protoporphyria mouse model.

  2006cited by this paper
• Uroporphyrinogen III synthase knock-in mice have the human congenital erythropoietic porphyria phenotype, including the characteristic light-induced cutaneous lesions.

  2006cited by this paper
• Prevention of murine erythropoietic protoporphyria-associated skin photosensitivity and liver disease by dermal and hepatic ferrochelatase.

  2005cited by this paper
• Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels.

  2005cited by this paper
• Genome-wide analysis of retroviral DNA integration

  2005cited by this paper
• Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy.

  2005cited by this paper
• Liver transplantation for erythropoietic protoporphyria liver disease

  2005cited by this paper
• A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia.

  2005cited by this paper
• Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Günther disease)

  2005cited by this paper
• Retroviral gene therapy: safety issues and possible solutions.

  2005cited by this paper
• Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection

  2004cited by this paper
• Congenital erythropoietic porphyria: report of a novel mutation with absence of clinical manifestations in a homozygous mutant sibling.

  2004cited by this paper
• Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.

  2004cited by this paper
• Liver pathology and hepatocarcinogenesis in a long‐term mouse model of erythropoietic protoporphyria

  2003cited by this paper
• A bicistronic SIN‐lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines

  2003cited by this paper
• In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning.

  2003cited by this paper
• Highly Efficient Lentiviral Gene Transfer in CD34+ and CD34+/38−/lin− Cells from Mobilized Peripheral Blood after Cytokine Prestimulation

  2003cited by this paper
• Lentivirus-mediated gene transfer of uroporphyrinogen III synthase fully corrects the porphyric phenotype in human cells

  2003cited by this paper
• American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells.

  2003cited by this paper
• An exon 10 deletion in the mouse ferrochelatase gene has a dominant-negative effect and causes mild protoporphyria.

  2002cited by this paper
• Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for myelogenous leukemia in a patient heteroallelic for ferrochelatase gene mutations.

  2002cited by this paper
• Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning

  2002cited by this paper
• Congenital erythropoietic porphyria: identification and expression of eight novel mutations in the uroporphyrinogen III synthase gene

  2002cited by this paper
• Treatment of recurrent allograft dysfunction with intravenous hematin after liver transplantation for erythropoietic protoporphyria.

  2002cited by this paper
• A mouse model of familial porphyria cutanea tarda.

  2001cited by this paper
• Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells

  2001cited by this paper
• Correction of deficient CD34+ cells from peripheral blood after mobilization in a patient with congenital erythropoietic porphyria.

  2001cited by this paper
• High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors.

  2001cited by this paper
• Uroporphyrinogen III synthase erythroid promoter mutations in adjacent GATA1 and CP2 elements cause congenital erythropoietic porphyria.

  2001cited by this paper
• Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection.

  2001cited by this paper
• Uroporphyria in Hfe mutant mice given 5‐aminolevulinate: A new model of Fe‐mediated porphyria cutanea tarda

  2001cited by this paper
• Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

  2000cited by this paper
• Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences

  2000cited by this paper
• Zebrafish dracula encodes ferrochelatase and its mutation provides a model for erythropoietic protoporphyria.

  2000cited by this paper
• Limiting numbers of G156A O(6)-methylguanine-DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection.

  2000cited by this paper
• The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells.

  2000cited by this paper
• Human uroporphyrinogen-III synthase: genomic organization, alternative promoters, and erythroid-specific expression.

  2000cited by this paper
• Reversion of hepatobiliary alterations by bone marrow transplantation in a murine model of erythropoietic protoporphyria

  2000cited by this paper
• Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy

  1999cited by this paper
• Ferrochelatase.

  1999cited by this paper
• Correction of uroporphyrinogen decarboxylase deficiency (hepatoerythropoietic porphyria) in Epstein-Barr virus-transformed B-cell lines by retrovirus-mediated gene transfer: fluorescence-based selection of transduced cells.

  1999cited by this paper
• Characterization of the P140K, PVP(138-140)MLK, and G156A O6-Methylguanine-DNA Methyltransferase Mutants: Implications for Drug Resistance Gene Therapy

  1999cited by this paper
• Biliary fibrosis associated with altered bile composition in a mouse model of erythropoietic protoporphyria.

  1999cited by this paper
• Congenital erythropoietic porphyria: prolonged high-level expression and correction of the heme biosynthetic defect by retroviral-mediated gene transfer into porphyric and erythroid cells.

  1998cited by this paper
• HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells.

  1998cited by this paper
• A zebrafish model for hepatoerythropoietic porphyria

  1998cited by this paper
• Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery

  1998cited by this paper
• Gene transfer of the uroporphyrinogen III synthase cDNA into haematopoietic progenitor cells in view of a future gene therapy in congenital erythropoietic porphyria

  1997cited by this paper
• In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector

  1996cited by this paper
• Correction of the enzyme deficit of bone marrow cells in congenital erythropoietic porphyria by retroviral gene transfer.

  1996cited by this paper
• Amelioration of the metabolic defect in erythropoietic protoporphyria by expression of human ferrochelatase in cultured cells.

  1995cited by this paper
• Correction of the Enzyme Defect in Cultured Congenital Erythropoietic Porphyria Disease Cells by Retrovirus-Mediated Gene Transfer

  1995cited by this paper
• [Congenital erythropoietic porphyria. Apropos of a fatal case in the neonatal period due to acute hemolysis with hepatic failure].

  1995cited by this paper
• Metabolic correction of congenital erythropoietic porphyria by retrovirus-mediated gene transfer into Epstein-Barr virus-transformed B-cell lines.

  1995cited by this paper
• HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator.

  1995cited by this paper
• Porphyrias: Animal models and prospects for cellular and gene therapy

  1995cited by this paper
• Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus

  1994cited by this paper
• A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells

  1993cited by this paper
• Ferrochelatase structural mutant (Fechm1Pas) in the house mouse.

  1993cited by this paper
• Erythropoietic protoporphyria in the house mouse. A recessive inherited ferrochelatase deficiency with anemia, photosensitivity, and liver disease.

  1991cited by this paper
• Heme synthesis in protoporphyria.

  1991cited by this paper
• Pathophysiology of cutaneous lesions in porphyrias.

  1989cited by this paper

• Hepatic Porphyria Presenting with Persistent Abdominal Pain: A Case Report and Literature Review

  2025cites this paper
• Exploring current and emerging therapies for porphyrias

  2024cites this paper
• Mutation-Specific Guide RNA for Compound Heterozygous Porphyria On-target Scarless Correction by CRISPR/Cas9 in Stem Cells

  2020influential citation
• Iron chelation rescues hemolytic anemia and skin photosensitivity in congenital erythropoietic porphyria.

  2020cites this paper
• CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations

  2019cites this paper
• The Investigation of Red Cell Mutants Identified in an ENU Mutagenesis Screen

  2019cites this paper
• Genetic background influences hepcidin response to iron imbalance in a mouse model of hemolytic anemia (Congenital erythropoietic porphyria).

  2019cites this paper
• Rare Genetic Blood Disease Modeling in Zebrafish

  2018cites this paper
• Erythropoietic protoporphyria in an adult with sequential liver and hematopoietic stem cell transplantation: A case report

  2018cites this paper
• A mouse model of hereditary coproporphyria identified in an ENU mutagenesis screen

  2017cites this paper
• A Novel Mutation in the FECH Gene in a Czech Family with Erythropoietic Protoporphyria and a Population Study of IVS3-48C Variant Contributing to the Disease.

  2015influential citation
• Molekulární patologie vybraných porfyrií s kožní manifestací Molecular pathology of selected porphyrias with skin manifestation

  2015cites this paper
• Tuning intracellular homeostasis of human uroporphyrinogen III synthase by enzyme engineering at a single hotspot of congenital erythropoietic porphyria.

  2014cites this paper
• Influence of iron metabolism on gene expression in erythropoietic protoporphyria

  2014cites this paper
• Heme in pathophysiology: a matter of scavenging, metabolism and trafficking across cell membranes

  2014cites this paper
• Therapeutic potential of proteasome inhibitors in congenital erythropoietic porphyria

  2013cites this paper
• USING FLUORESCENCE OF BONES AND TEETH TO DETECT REMAINS OF THE EASTERN FOX SQUIRREL (SCIURUS NIGER) IN ARCHAEOLOGICAL DEPOSITS

  2013cites this paper
• Cutaneous porphyrias part I: epidemiology, pathogenesis, presentation, diagnosis, and histopathology

  2013cites this paper
• Disorders of Haem Biosynthesis

  2012cites this paper
• Biothérapies des porphyries érythropoïétiques : thérapie cellulaire, thérapie génique et approche pharmacologique

  2012influential citation
• Metabolic correction of congenital erythropoietic porphyria with iPSCs free of reprogramming factors.

  2012cites this paper
• From the Dermatologikum Hamburg: Quiz

  2012cites this paper
• Fluorescence Provides Evidence of Congenital Erythropoietic Porphyria in 7000-Year-Old Specimens of the Eastern Fox Squirrel (Sciurus niger) from the Devil's Den

  2012cites this paper
• Congenital erythropoietic porphyria with two mutations of the uroporphyrinogen III synthase gene (Cys73Arg, Thr228Met)

  2011cites this paper
• Structural, thermodynamic, and mechanistical studies in uroporphyrinogen III synthase: molecular basis of congenital erythropoietic porphyria.

  2011cites this paper
• Neonatal bone marrow transplantation prevents liver disease in a murine model of erythropoietic protoporphyria.

  2011cites this paper
• Metal-complex formation and DNA interaction of 5, 10,15,20-tetrakis(1-methyl-4-pyridiyl)-porphine: Study of the mechanistic aspects

  2010cites this paper
• Liver disease and erythropoietic protoporphyria: a concise review.

  2010cites this paper
• The Porphyrias: Clinic, Diagnostics, Novel Investigative Tools and Evolving Molecular Therapeutic Strategies

  2010cites this paper
• Congenital erythropoietic porphyria: mutation update and correlations between genotype and phenotype.

  2009cites this paper